Artelon® STT Spacer receives regulatory clearance for marketing in the USA

Artelon® STT Spacer receives regulatory clearance for marketing in the USA

Västra Frölunda, Sweden, June 29, 2007
The biomaterials company Artimplant receives regulatory clearance for marketing
Artelon® STT Spacer in the USA.

The product is indicated for osteoarthritis in the STT joint. Small Bone
Innovations, the licensee of Artimplant, now gets the opportunity to market the
product at its domestic market USA. Patients in the USA with osteoarthritis in
both the CMC and STT joints that previously could not be treated for thumb base
osteoarthritis with only Artelon® CMC Spacer will as of now have the possibility
to benefit from Artimplant's Artelon® Spacers in both joints. 

President and CEO Hans Rosén says; “Artelon® STT Spacer is an important
complement to our currently best selling product Artelon® CMC Spacer. In
addition each new Artelon® product that receives regulatory clearance increases
market awareness of the unique capacity of Artelon® in various medical
applications.”


For additional information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Web site: www.artimplant.com

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.


Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.